7 unknown, 6 completed, 1 active not recruiting, 1 recruiting. 5 Phase 1, 2 Phase 4, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 5 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Anticoagulant: new trials by email Literature Review of Anticoagulant trials Research Report on Anticoagulant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration Heparin - Anticoagulant | Phase 1 | Unknown | Blau Farmaceutica S.A. | 68 | 2023-06-01 | 2023-03-29 |
| Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration Heparin - Anticoagulant | Phase 1 | Unknown | Blau Farmaceutica S.A. | 68 | 2023-06-01 | 2023-03-29 |
| Study of Low Molecular Weight Heparins Dalteparin Prefilled Syringe, Tinzaparin profiled syringe - Anticoagulant, Venous Thromboembolism | Phase 4 | Unknown | Herlev Hospital | 65000 | 2023-03-23 | 2023-08-31 |
| A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Lixiana(D006), CKD-344 - Anticoagulant | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 60 | 2021-04-27 | 2021-04-30 |
| A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition WD-1602, Pradaxa® - Anticoagulant | Phase 1 | Unknown | Hong Kong WD Pharmaceutical Co., Limited | 20 | 2021-01-06 | 2020-11-02 |
| Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) Sulodexide, Sulodexide and placebo, Placebo - Venous Thromboembolism, Anticoagulant | Phase 3 | Recruiting | Arianna Anticoagulazione Foundation | 1455 | 2020-12-21 | 2024-07-31 |
| A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 Lixiana(D006), CKD-344 - Anticoagulant | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 50 | 2020-11-13 | 2020-12-17 |
| Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics Dosage of S100β protein - Mild Head Injury, Anticoagulant | Completed | Rennes University Hospital | 260 | 2020-03-09 | 2023-04-12 | |
| Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON) Edoxaban Monotherapy - Acute Ischemic Stroke, Atrial Fibrillation | Active not recruiting | Asan Medical Center | 1200 | 2019-10-08 | 2025-07-11 | |
| Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians Survey, Venous Thromboembolism | Completed | Centre Hospitalier Universitaire, Amiens | 383 | 2019-08-21 | 2023-07-12 | |
| Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study 12-month Edoxaban, 3-month Edoxaban - Venous Thrombosis, Neoplasms | Phase 4 | Completed | Takeshi Morimoto | 605 | 2019-05-27 | 2023-10-04 |
| A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity Anti Xa levels - Anticoagulant, Apixaban | Completed | HaEmek Medical Center, Israel | 82 | 2019-05-06 | 2020-04-01 | |
| Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban Rivaroxaban - Cerebrovascular Stroke, Intracranial Hemorrhages | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 400 | 2019-01-18 | 2023-04-18 | |
| Determinants of Oral Anticoagulants' Activity PK-PD genetic polymorphisms - Anticoagulant | Terminated | University Hospital, Lille | 3 | 2017-07-06 | 2019-10-18 | |
| Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care acenocoumarol, control - Anticoagulant, Pharmacogenetics | Not applicable | Completed | Universidad San Jorge | 204 | 2017-05-22 | 2021-05-04 |
| Evaluation of Patient's Knowledge of Their NACO Treatment Anticoagulant | Completed | Fondation Hôpital Saint-Joseph | 51 | 2016-12-05 | 2018-02-27 |
Venous Thromboembolism (3) · Venous Thrombosis (2) · Atrial Fibrillation (1) · Brain Injuries, Traumatic (1) · Coronary Artery Disease (1) · Intracranial Arteriosclerosis (1) · Intracranial Hemorrhage, Traumatic (1) · Intracranial Hemorrhages (1) · Ischemic Stroke (1) · Neoplasms (1) · Obesity (1) · Pulmonary Embolism (1) · Stroke (1)
Cardiovascular Diseases (7) · Vascular Diseases (7) · Embolism and Thrombosis (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Cerebrovascular Disorders (3) · Nervous System Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Thromboembolism (3) · Pathologic Processes (2) · Thrombosis (2) · Arrhythmias, Cardiac (1) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Body Weight (1)
Drug Evaluation (2) · Heparin (2) · edoxaban (2) · Acenocoumarol (1) · Dabigatran (1) · Rivaroxaban (1) · glucuronyl glucosamine glycan sulfate (1)
Blau Farmaceutica S.A. (2) · Chong Kun Dang Pharmaceutical (2) · Arianna Anticoagulazione Foundation (1) · Asan Medical Center (1) · Centre Hospitalier Universitaire, Amiens (1) · Fondation Hôpital Saint-Joseph (1) · HaEmek Medical Center, Israel (1) · Herlev Hospital (1) · Hong Kong WD Pharmaceutical Co., Limited (1) · Rennes University Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Takeshi Morimoto (1) · Universidad San Jorge (1) · University Hospital, Lille (1)
France (4) · South Korea (3) · China (1) · Denmark (1) · Israel (1) · Italy (1) · Japan (1) · Spain (1)
Yook-Hwan Noh (2) · Corrado Lodigiani, MD,PhD (1) · Dominique Deplanque, MD, PhD (1) · Min Lou, PhD (1) · Simon Soudet, MD (1) · Sun U. Kwon, MD, PhD (1) · Takeshi Kimura, MD, PhD (1)
PMID 32451933, PMID 37638968, PMID 37704534, PMID 38650055, PMID 40766276, PMID 41444519
2019 (1)